Read by QxMD icon Read

Neurodegenerative Disease Management

Hanan Khalil, Monica Busse, Lori Quinn, Mohammad Nazzal, Waleed Batyha, Shatha Alkhazaleh, Mahmoud A Alomari
AIM: This study aimed to evaluate the feasibility and cultural considerations of a minimally supervised, home-based exercise program in Jordan. METHODS: Quantitative and qualitative approaches were used. Thirty participants were randomly allocated to either an 8-week intervention group (n = 16), or a standard care group (n = 14). The intervention incorporated the home use of an exercise DVD, walking program and initial instructional sessions and weekly phone calls provided by a physiotherapist...
January 18, 2017: Neurodegenerative Disease Management
Rachel E Klaren, Elizabeth A Hubbard, Nathan C Wetter, Bradley P Sutton, Robert W Motl
AIM: This study examined the association between sedentary behavior patterns and whole brain gray matter (GM), white matter (WM) and subcortical GM structures in persons with multiple sclerosis (MS). METHODS: 36 persons with MS wore an accelerometer and underwent a brain MRI. Whole brain GM and WM and deep GM structures were calculated from 3D T1-weighted structural brain images. RESULTS: There were statistically significant (p < 0.01) and moderate or large associations between number of sedentary bouts/day and brain volume measures...
January 11, 2017: Neurodegenerative Disease Management
Dennis A Davey
Alzheimer's disease, cerebrovascular disease and aging-related cognitive impairment and dementia (ARCID) increase in prevalence in women with advancing age. The development of Alzheimer's disease, cerebrovascular disease and ARCID may be postponed or prevented by protective measures including the active treatment of vascular risk factors and continuing exercise and healthy lifestyle from early- and mid-life onward. Bilateral oophorectomy before the natural menopause is associated with an increased incidence of ARCID and the increased risk is significantly reduced by estrogen therapy...
January 11, 2017: Neurodegenerative Disease Management
Barry Hendin, DeRen Huang, Sibyl Wray, Robert T Naismith, Sheri Rosenblatt, Javier Zambrano, Brian Werneburg
AIM: The objective of this Delphi analysis was to obtain consensus on injection-site reaction (ISR) experience and mitigation strategies for patients with relapsing-remitting multiple sclerosis switching from nonpegylated interferons (IFNs) to peginterferon β-1a in the ALLOW Phase IIIb trial using a three-step approach. METHODS: Study investigators and coordinators from investigative sites enrolling four or more patients in ALLOW participated in three rounds of questionnaires and interviews...
January 10, 2017: Neurodegenerative Disease Management
Ralph Kern
Ralph Kern speaks to Laura Dormer, Commissioning Editor: Dr Ralph Kern is Senior Vice President and Head of Worldwide Medical at Biogen in Cambridge, MA, USA. In this role, he oversees Biogen's global therapeutic, regional and country medical teams, global medical operations, as well as medical research and scientific communications functions. Prior to joining Biogen, he was head of the Neuroscience Medical Unit at Novartis Pharmaceuticals Corporation and held various medical and commercial leadership roles at Genzyme Corporation...
January 10, 2017: Neurodegenerative Disease Management
Aaron E Miller
Teriflunomide, a once-daily, oral disease-modifying therapy, has demonstrated efficacy in patients with relapsing forms of multiple sclerosis (MS) and patients with a first clinical episode suggestive of MS. As the only disease-modifying therapy with positive disability results in two Phase III trials, teriflunomide significantly slowed disability in patients with relapsing forms of MS. We highlight data from the Phase II study and the TEMSO, TOWER, TOPIC and TENERE teriflunomide studies. TEMSO MRI outcomes have been supported with Structural Image Evaluation Using Normalization of Atrophy analyses...
December 12, 2016: Neurodegenerative Disease Management
Victoria Hayes, Apo Demirkol, Nicole Ridley, Adrienne Withall, Brian Draper
Excessive alcohol use is associated with a wide range of physical, psychological and social consequences, and is responsible for a significant proportion of the burden of disease globally. An area which has received increasing interest is alcohol-related brain damage, not just because of the cost to the individual and society through resource utilization, but also because of the potential for prevention and reversibility. This paper aims to review the current literature on this subject and seeks to explore issues around diagnosis and treatment of alcohol-related brain damage...
November 18, 2016: Neurodegenerative Disease Management
Elizabeth Chmelik, Reiko Emtman, Anna Borisovskaya, Soo Borson
Dementia is a progressive neurodegenerative illness that affects a growing number of older adults in our country. We discuss ways to improve the management of persons with dementia within current healthcare models. Specifically, we argue that structured communication at regular intervals is essential for dementia care at all phases of illness. We emphasize the need for a single healthcare provider to take on a central role in organizing communication between patient, family and other healthcare providers in the outpatient setting...
November 18, 2016: Neurodegenerative Disease Management
Selina Chow, Ronald Chow, Michael Lam, Leigha Rowbottom, Drew Hollenberg, Erika Friesen, Olivia Nadalini, Henry Lam, Carlo DeAngelis, Nathan Herrmann
AIM: The aim of this review is to document pain assessment tools used primarily for older adults in long-term care facilities and compare self-report and observer-rated tools. METHODS: A literature search was conducted in Ovid MEDLINE(®), Embase, Cochrane and PsycINFO. Keywords included 'dementia', 'pain management' and 'managing pain'. RESULTS: Of 1033 references, 23 articles were selected for inclusion. Six tools were self-rated and 18 tools were administered by an observer...
November 18, 2016: Neurodegenerative Disease Management
Linda Lee, Loretta M Hillier
AIM: To identify family physicians' perception of the primary care collaborative memory clinic (PCCMC) care model. METHODS: Physicians with access to a PCCMC completed a survey to assess their satisfaction with various aspects of PCCMC care delivery (n = 78). Interviews were conducted with a purposeful sample of physicians (n = 20) to gather their opinions on the strengths, gaps in care and benefits associated with the PCCMC model. RESULTS: There was support for this care model in providing timely quality dementia care at a primary care level, making it easier for referring physicians to manage challenging aspects of dementia care...
November 9, 2016: Neurodegenerative Disease Management
Thomas Holtgraves
No abstract text is available yet for this article.
November 9, 2016: Neurodegenerative Disease Management
Hari S Sharma, Dafin F Muresanu, Aruna Sharma
No abstract text is available yet for this article.
November 9, 2016: Neurodegenerative Disease Management
Aleksandar Jovalekic, Santiago Bullich, Ana Catafau, Susan de Santi
Clinical diagnosis of Alzheimer's disease (AD) can be challenging as numerous diseases mimic the characteristics of AD. In this light, recent guidelines developed by different associations and working groups point out the need for biomarkers to support AD diagnosis. This paper discusses 18F-labeled radiotracers (which are indicated for PET imaging of the brain) and ongoing clinical studies that aim to generate new evidence for the usage of amyloid imaging. In addition to their relatively long half-life, these agents are known for their high sensitivity and high negative predictive values for detection of neuritic Aβ plaques...
November 4, 2016: Neurodegenerative Disease Management
Timothy Rittman, Ian Ts Coyle-Gilchrist, James B Rowe
Cognitive impairment is integral to the syndrome of progressive supranuclear palsy. It is most commonly described as a frontal dysexecutive syndrome but other impairments include apathy, impulsivity, visuospatial and memory functions. Cognitive dysfunction may be exacerbated by mood disturbance, medication and communication problems. In this review we advocate an individualized approach to managing cognitive impairment in progressive supranuclear palsy with the education of caregivers as a central component...
December 2016: Neurodegenerative Disease Management
Mathias Mäurer
No abstract text is available yet for this article.
December 2016: Neurodegenerative Disease Management
Giovanni Illomei
Ultrasound elastography is a novel imaging modality for evaluating the elasticity of biological tissues. The technique is widely used in oncology to detect and differentiate malignant lesions in soft tissues. Studies have explored use of ultrasound elastography to measure the mechanical properties of muscle in patients with multiple sclerosis spasticity. Real-time elastography was shown to correlate well with subjective scales commonly used to measure MS spasticity. Ultrasound elastography has the potential to become a new objective gold standard to monitor symptom evolution in patients with MS spasticity and to evaluate the efficacy of antispasticity treatment...
December 2016: Neurodegenerative Disease Management
Angelo Ghezzi
Each year at the MS Experts Summit, relevant research in the field of multiple sclerosis spasticity is featured in poster sessions. In 2016, six new studies were presented.
December 2016: Neurodegenerative Disease Management
Angelo Ghezzi, Linard Filli, Claudio Solaro, Claude Mekies, Lamberto Landete, Jan Lycke
At the 2016 MS Experts Summit, country-relevant aspects pertaining to the management of symptoms and disability in multiple sclerosis (MS), with emphasis on those associated with spasticity, were explored in interactive country breakout sessions chaired by selected MS experts. Attendees had the opportunity to review and discuss topics in their own native language. After feedback from each session leader, key messages were collated and presented in a Plenary Session by Summit chair, Professor Angelo Ghezzi. Topics at this year's Summit included: gait tracking (Germany/Switzerland); the Care Alliance against MS spasticity (Italy); MS spasticity and associated symptoms (France); improvement in MS symptoms and functionality and patients' independence (Spain); Swedish MS guidelines (Sweden/Rest of World)...
December 2016: Neurodegenerative Disease Management
Angelo Ghezzi
No abstract text is available yet for this article.
December 2016: Neurodegenerative Disease Management
Peter Flachenecker
In addition to muscle stiffness and increasing mobility restrictions, symptoms commonly associated with multiple sclerosis (MS) spasticity are spasms, sleep disturbances, pain, fatigue and bladder dysfunction. Treatment options include trigger factor avoidance, physiotherapy and antispasticity medication. Oral antispasticity agents commonly used in Germany are baclofen, tizanidine and gabapentin, but physician and patient satisfaction with their effectiveness is low. Over the past few years, randomized controlled trials, observational studies and registry data have demonstrated the positive risk:benefit profile of add-on 9-delta-tetra-hydrocannabinol:cannabidiol oromucosal spray for moderate-to-severe resistant MS spasticity...
December 2016: Neurodegenerative Disease Management
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"